PeptideStack
5.2kquestions
20kanswers
220users

glp1-mechanism

Page 2 of 6 · 132 questions tagged glp1-mechanism.

132 questions · sorted by votes · page 2 of 6

32 votes 5 answers36k views
How many weeks to steady state for tirzepatide on a weekly schedule?

I am asking mechanistically rather than practically — I want the model, not the protocol. I would rather understand the derivation than memorise the outcome. Two…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by cal_hennessy 17k · 13 months ago
32 votes 3 answers14k views
How does fatty-acid acylation turn a 2-minute peptide into a 7-day one?

Native GLP-1 has a plasma half-life measured in minutes. Semaglutide has one measured in days, and the difference is usually explained in one sentence about a fatty…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
asked by yuki_morishita 10k · 2.0 years ago
31 votes5 answers38k views
Is there a pharmacokinetic case for moving orforglipron injection day by three days?

Details up front: orforglipron · three days. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather…

missed-dose
missed-dose

What the label instructions for a missed weekly dose are, why they differ between agents, and what the pharmacokinetics say about drift in an…

41 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by coring_risk 27k · 14 months ago
31 votes 5 answers25k views
Does splitting a 2.4 mg weekly dose of mazdutide across two administrations change anything?

What I am working with: 2.4 mg · mazdutide. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather…

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

44 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by s_bhattacharya 31k · 21 months ago
30 votes 5 answers49k views
Does splitting a 36 mg weekly dose of orforglipron across two administrations change anything?

Numbers first: 36 mg · orforglipron. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how confident…

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

44 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by leonid_marchuk 19k · 23 months ago
30 votes 5 answers40k views
Does splitting a 2.4 mg weekly dose of semaglutide across two administrations change anything?

The specifics, since they change the answer: 2.4 mg · semaglutide. I would like the mechanism, because I want to be able to reason about the cases nobody has written…

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

44 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by e_dziedzic 51k · 2.0 years ago
30 votes5 answers36k views
What does the mechanism of semaglutide predict that STEP 1 did not test?

Conditions: semaglutide · STEP 1. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by seven_day_half 31k · 15 months ago
30 votes0 answers19k views
Does splitting a 14 mg weekly dose of oral semaglutide across two administrations change anything?

Concretely: 14 mg · oral semaglutide. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

44 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by jana_horakova 10k · 10 months ago
28 votes 5 answers12k views
Does injecting into the outer thigh change absorption enough to matter?

I keep a written log of every draw with date, volume and syringe type. I understand the observation; what I do not understand is the mechanism behind it. I have read…

subcutaneous
subcutaneous

Subcutaneous administration as a route: absorption kinetics from abdomen versus thigh versus upper arm, tissue depth, and why site rotation…

10 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by anouk_desmet 16k · 14 months ago
28 votes1 answer11k views
Does splitting a 5 mg weekly dose of ecnoglutide across two administrations change anything?

The specifics, since they change the answer: 5 mg · ecnoglutide. I would like the mechanism, because I want to be able to reason about the cases nobody has written…

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

44 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
asked by seamus_brady 15k · 8 months ago
27 votes5 answers35k views
How many weeks to steady state for orforglipron on a weekly schedule?

This matters because it predicts what a related molecule should do. The units are where I keep going wrong, so please be explicit about them. I have sanity-checked…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by gradient_slope 46k · 17 months ago
27 votes 3 answers11k views
Why is oral semaglutide only about 1% bioavailable, and what is SNAC actually doing?

I understand in general terms that peptides do not survive oral administration - stomach acid, proteases, and a wall of epithelium that evolved specifically to keep…

oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by sample_id 17k · 22 months ago
27 votes 3 answers6.9k views
How much of the weight effect is delayed gastric emptying, and is the plateau receptor desensitisation?

Two related mechanism questions I have never seen answered together. First, how much of the weight loss is attributable to delayed gastric emptying as opposed to…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
plateau
plateau

A stall in progress: distinguishing adaptive thermogenesis from measurement error from adherence drift, how long to observe before changing…

36 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
asked by syringe_ninety 12k · 3 months ago
26 votes0 answers6.5k views
What does the mechanism of semaglutide predict that STEP 4 did not test?

What I am working with: semaglutide · STEP 4. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by bridget_nyathi 12k · 12 months ago
25 votes4 answers13k views
Why is the titration interval four weeks and not two?

The label documentation for the agent in question is ambiguous on exactly this point. This is one of those things that everyone repeats and nobody derives. This…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by Dr_Colm_Fitzhenry 69k · 11 months ago
24 votes 4 answers34k views
What does the mechanism of oral semaglutide predict that SOUL did not test?

The specifics, since they change the answer: oral semaglutide · SOUL. I would like the mechanism, because I want to be able to reason about the cases nobody has…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by zainab_mustafa 21k · 2.2 years ago
23 votes 5 answers36k views
What does the mechanism of tirzepatide predict that SURPASS-3 did not test?

Conditions: tirzepatide · SURPASS-3. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by jana_horakova 10k · 20 months ago
23 votes 5 answers9k views
How does fatty-acid acylation produce a seven-day half-life?

I would like to know how much of this is established and how much is a reasonable story. I would like the mechanism, because I want to be able to reason about the…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by tabular_nums 71k · 3 months ago
23 votes3 answers8.9k views
What does orforglipron being a non-peptide small molecule change, practically?

Orforglipron is described as a non-peptide oral GLP-1 receptor agonist, which I take to mean it is a conventional small molecule rather than a peptide with a delivery…

orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by ruaidhri_o_shea 25k · 9 months ago
23 votes 3 answers7.7k views
GLP-1R signalling: what does biased agonism at a class B GPCR actually mean here?

I can follow the basic signalling story: GLP-1 receptor is a Gs-coupled receptor, activation raises cAMP, protein kinase A does things, and in the beta cell that…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by pip_okonjo 13k · 11 months ago
22 votes 5 answers23k views
Does injecting into the abdomen change absorption enough to matter?

I have photographs before and after reconstitution if the visual detail matters. I keep seeing this stated as a fact with no explanation attached, and unexplained…

subcutaneous
subcutaneous

Subcutaneous administration as a route: absorption kinetics from abdomen versus thigh versus upper arm, tissue depth, and why site rotation…

10 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by area_percent 9.9k · 15 months ago
22 votes1 answer9.3k views
Why does amylin co-agonism add to a GLP-1 effect rather than duplicate it?

I am asking mechanistically rather than practically — I want the model, not the protocol. I can predict the outcome but I cannot explain it, which means I will get…

amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
cagrisema
cagrisema

A fixed-ratio combination of cagrilintide, a long-acting amylin analogue, with semaglutide, studied in the REDEFINE programme. Questions here…

8 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by cake_intact 17k · 11 months ago
21 votes 5 answers42k views
What does the mechanism of oral semaglutide predict that PIONEER-4 did not test?

For reference: oral semaglutide · PIONEER-4. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by h_villanueva 70k · 2.0 years ago
21 votes0 answers20k views
Is there a pharmacokinetic case for moving mazdutide injection day by five days?

Conditions: mazdutide · five days. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how confident…

missed-dose
missed-dose

What the label instructions for a missed weekly dose are, why they differ between agents, and what the pharmacokinetics say about drift in an…

41 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by cake_intact 17k · 14 months ago